|By PR Newswire||
|December 18, 2012 09:39 PM EST||
IRVINE, Calif., Dec. 18, 2012 /PRNewswire/ -- Dr. Douglas Harrington, CEO of Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, led a dynamic and innovative presentation on Monday, December 10th at the Middle East Health Congress entitled "Practical Mechanisms To Promote Healthy Lifestyles" along with moderator Laura Putman and panelist, Dr. Fadia Al Buhairan.
The panel's discussion was based upon evidence that healthy habits implemented early on in life are more likely to create life-long habits, which ensure a healthy adult life.
In addition to the speaking panel, Aviir also participated as an exhibitor at the Middle East Health Congress. "Aviir is proud to be a part of the 2012 Middle East Health Congress. This innovative Congress provides a great opportunity for health care, government and industry leaders to discuss challenges in the health care system and offer innovative solutions to global issues," said Harrington.
As CEO of Aviir, Dr. Harrington brings more than 25 years of experience in the discovery and creation of unique laboratory tests to guide clinical decisions. Aviir's mission is to advance Heart Disease prevention by giving doctors everywhere the proper tools to better identify those who are at risk at an early stage. Developed by Aviir through a Stanford University cardiology collaboration, Aviir's proprietary blood test, MIRISK VP, was showcased at the event and identifies an individuals' cardiac risk in a five-year timeframe. By introducing MIRISK VP technology into various regions of the Middle East, Aviir hopes to stop the rapidly increasing death rate from Heart Disease, a global epidemic. The good news is that this disease is highly preventable and even reversible, if identified in the early stages, by using MIRISK VP.
About Aviir, Inc.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.
ABOUT THE MIDDLE EAST HEALTH CONGRESS
The Third Annual Middle East Health Congress was hosted this year at the Sofitel in Abu Dhabi and co-sponsored by the Health Authority Abu Dhabi and the Abu Dhabi Tourism Authority. It is the premier conference in the region and brings together over 600 health care, government and industry leaders from over 25 countries.
For media inquiries, please contact:
Dina Scaglione, Corporate Media Manager
SOURCE Aviir Inc.